By Ane Quesada, senior scientist – MSAT, Viralgen and Joschka Buyel, principal product scientist, QbDVision
Reactive, highly manual reviews to disparate data pools. Uneven version control. Siloed, disconnected information streams. The factors standing in the way of today’s streamlined tech transfer are many and varied.
So the need for solutions that convene, collate, and cohere data to support decision-making and drive results has perhaps never been greater. Enter QbDVision, a structured, cloud-based platform that serves as the industry’s first digital chemistry, manufacturing, and controls (CMC) toolbox. In simplest terms, it enables greater standardization, improved transparency, and increased data confidence, paving the way for smoother tech transfer and faster commercial readiness.
By combining the digital CMC backbone that QbDVision provides with data generated through Viralgen’s own Aava™ platform process, Viralgen was able to onboard a gene therapy manufacturing client in just three months – a dramatic reduction from the average industry timeline of six to twelve months.
Get the full details in our whitepaper: Digital Standardization: Accelerating Gene Therapy Tech Transfer with Confidence and Compliance
